Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation

Annals of Hematology
C GemmelH Goldschmidt

Abstract

In multiple myeloma (MM), circulating malignant B cells are proposed as the proliferative compartment of the disease. In view of the close relationship between multiple myeloma and primary plasma cell leukemia (PCL), an anti-CD20 antibody treatment might also be considered as consolidation for patients with PCL. A 55-year-old patient diagnosed with PCL achieved complete remission after autologous transplantation. A total of four weekly courses of rituximab (375 mg/m(2)) were administered. Prior to antibody therapy, CD20+ cells comprised 22.6% of the mononuclear cells in peripheral blood (PB) assessed by flow cytometry and were enriched by magnetic activated cell sorting (MACS). In the enriched CD20+ fraction, 0.093% clonotypic cells were detected using a quantitative polymerase chain reaction (PCR) assay based on limiting dilutions. The proportion of clonotypic cells was 0.034% in PB and 0.032% in bone marrow (BM). Rituximab depleted CD20+ cells completely in PB and BM. Tumor load in PB and BM at day 40 and in PB at day 70 did not change in comparison to prior to therapy (0.037% in PB, 0.026% in BM). At day 90, the tumor load increased to 0.066% in PB. At day 120, the patient relapsed with 0.65% CD38++/CD138+/CD20- plasma cells...Continue Reading

Citations

Jan 18, 2006·Annals of Hematology·Víctor Hugo Jiménez-Zepeda, Virginia Jeanet Domínguez
Aug 7, 2007·International Journal of Hematology·P BrückJ Atta
Nov 3, 2011·Bone Marrow Research·Yu-Tzu Tai, Kenneth C Anderson
Jul 2, 2011·Critical Reviews in Oncology/hematology·Pellegrino MustoAntonio Palumbo
Mar 1, 2007·Transplant International : Official Journal of the European Society for Organ Transplantation·Dirk R J KuypersYves Vanrenterghem
Mar 6, 2008·British Journal of Haematology·Prashant KapoorPhilip R Greipp
Aug 13, 2010·British Journal of Haematology·Taimur SherAsher Chanan-Khan
Mar 20, 2013·European Journal of Haematology·Alessandro AllegraCaterina Musolino
Oct 8, 2015·Clinical Lymphoma, Myeloma & Leukemia·Sandy W Wong, Raymond L Comenzo
Jul 16, 2010·British Journal of Haematology·Gabriele BudaMario Petrini
Feb 19, 2013·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Taiga NishihoriMohamed A Kharfan-Dabaja
Jul 28, 2012·Blood·Niels W C J van de DonkPaul G Richardson
Mar 17, 2004·Cancer Control : Journal of the Moffitt Cancer Center·Cristina Gasparetto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B cell Differentiation

Depending on the signal received through the B cell receptor and other receptors, B cells differentiate into follicular or marginal zone B cells. Here is the latest research pertaining to this differentiation process.